Results from the 208-Week (4-Year) Follow-up of RESPONSE trial, a phase 3 study comparing ruxolitinib (Rux) with best available therapy (BAT) for the treatment of polycythemia vera (PV)

Authors
Category Primary study
JournalBlood
Year 2017
This article has no abstract
Epistemonikos ID: d1c0feae46deb2c95d278719bbd2436cafab9fb7
First added on: Feb 08, 2025